ReviewTrends in molecular medicine2018
IL-1 Family Cytokine Pathways Underlying NAFLD: Towards New Treatment Strategies.
Review in Trends in molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 2 syntheses or guidelines pooled it, 133 citations in OpenAlex.
- Therapeutic potential of Akkermansia muciniphila in non-alcoholic fatty liver disease: a systematic review.BMC gastroenterology · 2025Pooled it
- Risk of liver dysfunction and non-alcoholic fatty liver diseases in people with hidradenitis suppurativa: A systematic review and meta-analysis of real-world evidences.Frontiers in immunology · 2022Pooled it
- Interleukin-1β in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes.Cardiovascular diabetology · 2025Trial
- Multiomics Insights Linking Personal Care Products Exposure to Serum Lipid Profiles in Older Adults: The China BAPE Study.Environmental health perspectives · 2026Article
- Blue mussel (Mytilus edulis) lipid extract prevents metabolic dysfunction-associated steatotic liver disease.Journal of the science of food and agriculture · 2026Article
- The Liver-Testis Axis: Molecular Mechanisms and Clinical Implications.International journal of molecular sciences · 2026Review
- Article
- Article
- Advances in the pathogenesis of MASLD and its association with neutrophils.Frontiers in medicine · 2026Review
- Critical role of interleukin-33 in pathogenesis and progression of metabolic dysfunction-associated steatotic liver disease.Frontiers in medicine · 2026Review
- Hepatic lipid accumulation induced by mono-(2-ethylhexyl) phthalate and potential ERBB2-associated inflammatory signaling in NAFLD.Frontiers in pharmacology · 2026Article
- Human umbilical cord-derived mesenchymal stem cells ameliorate non-alcoholic fatty liver disease via activating TFEB-mediated autophagy in male mice.Stem cell research & therapy · 2025Article
- Risk factors for pulmonary function alterations in children with metabolic dysfunction-associated fatty liver disease.Scientific reports · 2025Article
- Adenosine deaminase and interleukin-1 receptor antagonist genetic polymorphisms among obese children with versus without metabolic dysfunction-associated fatty liver disease.Clinical and experimental pediatrics · 2025Article
- REG3A and IL22 have opposite effects on fat accumulation in the liver in a high-fat diet.Scientific reports · 2025Article
- Ganoapplanilactone C fromAntioxidants (Basel, Switzerland) · 2025Article
- Mechanistic insights into the P-coumaric acid protection against bisphenol A-induced hepatotoxicity in in vivo and in silico models.Scientific reports · 2025Article
- Metabolic dysfunction-associated steatotic liver disease in adults.Nature reviews. Disease primers · 2025Review
- Submicron Dispersions of Phytosterols Reverse Liver Steatosis with Higher Efficacy than Phytosterol Esters in a Diet Induced-Fatty Liver Murine Model.International journal of molecular sciences · 2025Article
- Halting Hypercaloric Feeding in Liver Chimeric Mice Rapidly Resolves Human Hepatocyte Steatosis.Gastro hep advances · 2025Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. Pathways responsible for the activation of IL-1 family cytokines are key in the development of NAFLD but underlying mechanisms are not fully understood. Many studies have focused on the inflammasome-caspase-1 pathway and have shown that this pathway is an important inducer of inflammation in NAFLD. However, this pathway is not solely responsible for the activation of proinflammatory cytokines. Also, neutrophil serine proteases (NSPs) are capable of activating cytokines and recent studies reported that these proteases also contribute to NAFLD. These studies provided, for the first time, evidence that this inflammasome-independent pathway is involved in NAFLD. In our opinion, these new insights open up new approaches for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.